Journal
TRANSPLANT IMMUNOLOGY
Volume 27, Issue 1, Pages 59-62Publisher
ELSEVIER
DOI: 10.1016/j.trim.2012.06.003
Keywords
HSCT; UCB; GVHD; ATG; Rabbit-IgG
Categories
Funding
- Children's Cancer Foundation [09/014]
- Swedish Society for Medical Research (SSMF)
- Swedish Research Council (VR)
Ask authors/readers for more resources
We determined total rabbit-IgG (r-ATG) levels in serum samples before (day 0) and after (day 11 and day 25) unrelated donor umbilical cord blood transplantation (UCBT). Most patients (27/41) suffered from a haematological malignancy. There were 25 children and 16 adults. All patients received rabbit anti-thymocyte globulin (ATG) at a total dose of 6 or 8 mg/kg as part of the conditioning. No correlation between the dose of ATG and serum r-ATG levels post UCBT was found. The cumulative incidence of acute GVHD grades III-IV in patients given the 6 and 8 mg/kg ATG dose was 15% and 13% (ns), respectively. Patients with r-ATG <= mu g/mL 11 days after UCBT (n = 19) had a higher incidence of grades III-IV acute GVHD (32% vs. 0%, p<0.01), higher TRM (69% vs. 7%, p = 0.005), less relapse (17% vs. 82%, p<0.01) but similar relapse-free survival (RFS) (10% vs. 18%, p = 0.4) compared to those with r-ATG>40 mu g/mL (n = 17). Low serum-levels of r-ATG early after transplantation seem to be a strong predictor for acute GVHD grades III-IV. TRM and a low incidence of relapse in patients treated with thymoglobulin before unrelated donor UCBT. (C) 2012 Elsevier BV. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available